20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 3 of 7

Topic	Participants	Replies	Views	Activity
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…	+3	7	1k	2mo
Comparing the STEP programme populations: who was actually enrolled Compounds › Semaglutide SELECT trial STEP programme semaglutide effect size Solved Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…		2	7.5k	2mo
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…		2	14k	2mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on Compounds › Oral incretins PIONEER programme SOUL trial orforglipron Solved Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…	+16	20	18k	2mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…	+119	136	5.6k	2mo
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 observational data Wiki Closed Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…	+2	6	31k	2mo
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Oral semaglutide bioavailability and its variability between people Compounds › Oral incretins SOUL trial oral semaglutide randomised trial Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…	+44	48	574	3mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis CJC-1295 ipamorelin tesamorelin needs a source On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…	+20	24	18k	4mo
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide effect size randomised trial SELECT trial On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…	+41	46	1.2k	4mo
[2026 update] Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides BPC-157 observational data TB-500 Solved Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it…	+15	19	11k	4mo
IGF-1 as a surrogate endpoint and its limitations Compounds › Secretagogues & GH axis GHRP class needs a source observational data tesamorelin IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…	+5	9	35k	4mo
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…	+73	79	2k	4mo
Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues cagrilintide amylin analogues cagrisema Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it…	+70	76	3k	4mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…	+128	145	3k	4mo
Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides BPC-157 observational data preprint TB-500 Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…	+20	24	47k	4mo
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset Compounds › Repair & healing peptides observational data preprint BPC-157 Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…	+64	69	27k	4mo
The most common factual error about semaglutide on the internet — what changed since Compounds › Semaglutide effect size randomised trial SELECT trial type 2 diabetes The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…	+42	46	1.7k	5mo
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues amylin analogues randomised trial effect size cagrisema Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+21	25	44k	5mo
Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide STEP programme SELECT trial randomised trial effect size Solved Closed Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…		2	63k	5mo
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+45	50	7.6k	5mo
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+100	104	4.2k	5mo
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Solved Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…		2	1.9k	5mo
[2026 update] Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Closed Posting this under the heading it deserves: Evidence quality in the secretagogue literature: an honest assessment Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…	+14	18	3.1k	6mo
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide SELECT trial STEP programme effect size randomised trial Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…		2	39k	6mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…	+25	35	568	6mo
AOD-9604 and the fragment hypothesis, revisited Compounds › Other compounds mislabelling research use only custom synthesis needs a source Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…	+40	44	2.8k	6mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…	+7	11	281	6mo